{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:57:38Z","timestamp":1790665058193,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008890","name":"University of Dundee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.resmer.2026.101323","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:00:44Z","timestamp":1789196444000},"page":"101323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identifying predictive baseline characteristics for super response to dupilumab in patients with severe uncontrolled asthma"],"prefix":"10.1016","volume":"90","author":[{"given":"Robert","family":"Greig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-2014","authenticated-orcid":false,"given":"Brian","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.resmer.2026.101323_bib0001","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.resmer.2026.101323_bib0002","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J Allergy Clin Immunol Pr"},{"issue":"6","key":"10.1016\/j.resmer.2026.101323_bib0003","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.anai.2025.03.013","article-title":"Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in real life","volume":"134","author":"Greig","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resmer.2026.101323_bib0004","article-title":"Identifying super-responders: a review of the road to asthma remission","author":"Mailhot-Larouche","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.resmer.2026.101323_bib0005","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.2500\/aap.2024.45.230072","article-title":"Real-world effectiveness and predictors of super-responders to dupilumab in a Chinese uncontrolled asthma cohort","volume":"45","author":"Chen","year":"2024","journal-title":"Allergy Asthma Proc"},{"issue":"3 Suppl","key":"10.1016\/j.resmer.2026.101323_bib0006","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jaci.2011.12.983","article-title":"Asthma outcomes: exacerbations","volume":"129","author":"Fuhlbrigge","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.resmer.2026.101323_bib0007","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.anai.2021.06.007","article-title":"Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma","volume":"127","author":"Chan","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resmer.2026.101323_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108203","article-title":"Clinical response and remission in patients treated with dupilumab for severe asthma: results from the nationwide Danish Severe Asthma Register","volume":"245","author":"Hansen","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.resmer.2026.101323_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.resmer.2026.101323_bib0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"super-responder\" to Mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.resmer.2026.101323_bib0011","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of Benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:13:21Z","timestamp":1790662401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041226000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":11,"alternative-id":["S2590041226000772"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101323","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying predictive baseline characteristics for super response to dupilumab in patients with severe uncontrolled asthma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101323"}}